Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: A phase 2 trial

Authors

• Tim Kong, Washington University School of Medicine in St. Louis
• Alex Mabry, Washington University School of Medicine in St. Louis
• Maureen Highkin, Washington University School of Medicine in St. Louis
• Jeremy Hoog, Washington University School of Medicine in St. Louis
• Zhanfang Guo, Washington University School of Medicine in St. Louis
• Adrian Gonzales-Gonzales, Washington University School of Medicine in St. Louis
• Shana Thomas, Washington University School of Medicine in St. Louis
• Yingduo Song, Washington University School of Medicine in St. Louis
• Feng Gao, Washington University School of Medicine in St. Louis
• Mateusz Opyrchal, Washington University School of Medicine in St. Louis
• Lindsay Peterson, Washington University School of Medicine in St. Louis
• Foluso Ademuyiwa, Washington University School of Medicine in St. Louis
• Julie Margenthaler, Washington University School of Medicine in St. Louis
• Rebecca Aft, Washington University School of Medicine in St. Louis
• Katherine Glover-Collins, Washington University School of Medicine in St. Louis
• Leslie Nehring, Washington University School of Medicine in St. Louis
• Yu Tao, Washington University School of Medicine in St. Louis
• Souzan Sanati, Washington University School of Medicine in St. Louis
• Ian S Hagemann, Washington University School of Medicine in St. Louis
• Fouad Boulos, Washington University School of Medicine in St. Louis
• Li Ding, Washington University School of Medicine in St. Louis
• Stephen T Oh, Washington University School of Medicine in St. Louis
• Ron Bose, Washington University School of Medicine in St. Louis
• Jason D Weber, Washington University School of Medicine in St. Louis
• Jingqin Luo, Washington University School of Medicine in St. Louis
• Cynthia X Ma, Washington University School of Medicine in St. Louis
• et al.

Journal

Nature Communications

Publication Date

1-27-2026

Volume

17

Issue

1

First Page

949

Document Type

Open Access Publication

DOI

10.1038/s41467-026-68570-6

Rights and Permissions

Kong, T., Mabry, A., Highkin, M. et al. Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial. Nat Commun 17, 949 (2026). https://doi.org/10.1038/s41467-026-68570-6 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Recommended Citation

Kong, Tim; Mabry, Alex; Highkin, Maureen; Hoog, Jeremy; Guo, Zhanfang; Gonzales-Gonzales, Adrian; Thomas, Shana; Song, Yingduo; Gao, Feng; Opyrchal, Mateusz; Peterson, Lindsay; Ademuyiwa, Foluso; Margenthaler, Julie; Aft, Rebecca; Glover-Collins, Katherine; Nehring, Leslie; Tao, Yu; Sanati, Souzan; Hagemann, Ian S; Boulos, Fouad; Ding, Li; Oh, Stephen T; Bose, Ron; Weber, Jason D; Luo, Jingqin; Ma, Cynthia X; and et al., "Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: A phase 2 trial." Nature Communications. 17, 1. 949 (2026).
https://digitalcommons.wustl.edu/oa_4/6456

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.